Predictors of myelodysplastic syndrome in Minnesota

明尼苏达州骨髓增生异常综合征的预测因子

• 批准号: 8617812
• 负责人: Jenny N. Poynter
• 金额: $ 50.57万
• 依托单位: UNIVERSITY OF MINNESOTA
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-04-01 至 2016-02-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8617812
• 关键词: Accounting; Acute Myelocytic Leukemia; Address; Adult; Adult Acute Myeloblastic Leukemia; Affect; Age; American; American Indians; Anti-Inflammatory Agents; Anti-inflammatory; Asians; Benzene; British; Cancer Center; Case-Control Studies; Categories; Cells; Cessation of life; Chemical Exposure; Chemicals; Chronic Myelomonocytic Leukemia; Classification; Clinic; Collection; Controlled Study; DNA; Data; Development; Diagnosis; Diet; Drug usage; Dysmyelopoietic Syndromes; Enrollment; Epidemiologic Studies; Epidemiology; Etiology; Exposure to; Family history of; Frequencies; Funding; Future; Genetic Predisposition to Disease; Genotype; Goals; Health; Hematologic Neoplasms; Hematopoietic Neoplasms; Hematopoietic System; Hispanics; Hospitals; Incidence; Individual; International; Knowledge; Lead; Letters; Literature; Malignant Glioma; Malignant Neoplasms; Medical Records; Minnesota; Myeloid Leukemia; Newly Diagnosed; Not Hispanic or Latino; Obesity; Occupational Exposure; Outcome; Overweight; Pacific Island Americans; Pathology; Patients; Personal Communication; Pesticides; Population Control; Positioning Attribute; Prevention; Prevention strategy; Process; Prognostic Factor; Public Health; Questionnaires; Radiation; Recording of previous events; Refractory anemias; Reporting; Research Infrastructure; Residual state; Rheumatoid Arthritis; Risk; Risk Factors; Role; SEER Program; Saliva; Solvents; Suggestion; Surveys; Susceptibility Gene; System; Time; United States; United States National Institutes of Health; World Health Organization; adult leukemia; base; case control; chemotherapy; cigarette smoking; comparative genomic hybridization; cost effective; follow-up; genetic analysis; high risk; improved; indexing; insight; leukemia; lifestyle factors; neoplasm registry; novel; pesticide exposure; population based; prognostic; public health relevance

DESCRIPTION (provided by applicant): Myelodysplastic syndrome (MDS) is a heterogeneous disruption of the hematopoietic system that can lead to the development of acute myeloid leukemia (AML) in about 1/3 of cases. MDS became reportable to the Surveillance, Epidemiology and End Results program in 2001. It is estimated that about 10,000 MDS cases are newly diagnosed each year in the United States, which is similar to the number of malignant gliomas. Minnesota has one of the higher incidence rates of MDS. With the exception of chemotherapy and radiation treatment for other cancers, which is associated with < 5% of MDS, little is known about causes. Of the few studies conducted (mostly <200 cases and/or clinic-based), there is a suggestion of a role for occupational exposures, cigarette smoking, and some other lifestyle factors, many of which are similar to those associated with AML. We are proposing a new population-based study of MDS in Minnesota that utilizes the questionnaire and infrastructure of our ongoing adult myeloid leukemia study that concludes in early 2010. A total of 705 MDS cases and 705 frequency-matched population controls will be enrolled over a 4 1/2 year period (April 1, 2010 - October 31, 2014). In addition to evaluating potential risk factors such as those described above, we will explore risk factors by central pathology reviewed subtypes of MDS by integrating data from our adult myeloid leukemia study. We will also determine those environmental or other exogenous risk factors that are common to AML and MDS versus those risk factors that are distinct. Additionally, we will explore whether there are risk factors more common to MDS cases that are at risk of progressing to AML, which includes the novel incorporation of prognostic scoring systems. Finally, we will collect saliva from MDS cases and controls for future genetic susceptibility studies. This study will be the largest population-based study of MDS conducted to date. With the incorporation of a successful infrastructure, and the ability to make comparisons with a similar existing study of myeloid leukemia, we are uniquely positioned to answer important etiological questions regarding MDS. The significance of this proposal also relates to potential prevention strategies for adult AML, which has important public health implications.

描述(申请人提供)：骨髓增生异常综合征(MDS)是一种异质性的造血系统紊乱，可导致约三分之一的病例发展为急性髓系白血病(AML)。2001年，MDS向监测、流行病学和最终结果方案报告。据估计，美国每年新诊断的MDS病例约为1万例，与恶性胶质瘤的数量相似。明尼苏达州是MDS发病率较高的州之一。除了与5%的MDS相关的其他癌症的化疗和放射治疗外，人们对其病因知之甚少。在为数不多的几项研究中(主要是200例病例和/或基于临床)，有研究表明职业暴露、吸烟和一些其他生活方式因素可能起到一定作用，其中许多因素与急性髓细胞白血病的相关因素相似。我们建议在明尼苏达州对MDS进行一项新的基于人群的研究，该研究利用了我们正在进行的成人髓系白血病研究的问卷和基础设施，该研究将于2010年初结束。在4年半的时间里(2010年4月1日至2014年10月31日)，总共将登记705例MDS病例和705例频率匹配的人口对照。除了评估上述的潜在危险因素外，我们还将结合我们成人髓系白血病研究的数据，通过中央病理复习的MDS亚型来探索危险因素。我们还将确定AML和MDS共有的环境或其他外源性风险因素与不同的风险因素。此外，我们将探索MDS病例中是否有更常见的危险因素有进展为AML的风险，其中包括新纳入的预后评分系统。最后，我们将收集MDS病例和对照的唾液，用于未来的遗传易感性研究。这项研究将是迄今为止对MDS进行的最大规模的基于人群的研究。随着一个成功的基础设施的加入，以及与现有的类似髓系白血病研究进行比较的能力，我们在回答有关MDS的重要病因学问题方面处于独特的地位。这项建议的意义还涉及成人急性髓细胞白血病的潜在预防战略，这具有重要的公共卫生影响。